schliessen

Filtern

 

Bibliotheken

Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series

This case series evaluates the clinical and ultrasound response to tocilizumab treatment in patients with rheumatoid arthritis (RA). Six patients with active RA (DAS28 ≥ 3.2) for ≥6 months, refractory to conventional DMARDs or anti-TNF agents, received tocilizumab 8 mg/kg every 4 weeks, as monothera... Full description

Journal Title: Rheumatology International 2014, Vol.34(5), pp.737-742
Main Author: Epis, Oscar
Other Authors: Filippucci, Emilio , Delle Sedie, Andrea , De Matthaeis, Anna , Bruschi, Eleonora
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0172-8172 ; E-ISSN: 1437-160X ; DOI: 10.1007/s00296-012-2638-3
Link: http://dx.doi.org/10.1007/s00296-012-2638-3
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s00296-012-2638-3
title: Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series
format: Article
creator:
  • Epis, Oscar
  • Filippucci, Emilio
  • Delle Sedie, Andrea
  • De Matthaeis, Anna
  • Bruschi, Eleonora
subjects:
  • Rheumatoid arthritis
  • Tocilizumab
  • Therapy monitoring
  • Ultrasonography
  • Power Doppler
ispartof: Rheumatology International, 2014, Vol.34(5), pp.737-742
description: This case series evaluates the clinical and ultrasound response to tocilizumab treatment in patients with rheumatoid arthritis (RA). Six patients with active RA (DAS28 ≥ 3.2) for ≥6 months, refractory to conventional DMARDs or anti-TNF agents, received tocilizumab 8 mg/kg every 4 weeks, as monotherapy or in combination with DMARDs, for 6 months. The following clinical parameters were assessed monthly: number of tender joints (28 and 44 joints), number of swollen joints (28 and 44 joints), DAS28-ESR, DAS28-CRP, VAS score, global health status, health assessment questionnaire, patient global assessment of disease activity, physician global assessment of disease activity, functional assessment of chronic illness therapy (FACIT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). All patients also underwent a gray-scale ultrasonography (US) assessment with power Doppler evaluation at each visit. All clinical parameters improved during the study, versus baseline. This improvement was statistically significant for most parameters 2 months following tocilizumab initiation and was sustained to the end of the observation period. The number of tender joints (44-joint evaluation), the FACIT score, and ESR and CRP concentrations were significantly improved versus baseline values after the first month of tocilizumab treatment. The course of US evaluations mirrored that of clinical parameters; a faster and more evident response was observed for foot joints, with respect to hand joints. This case series suggested the rapid clinical benefit of tocilizumab. Ultrasound assessment showed that the onset of this effect was faster in the foot joints than in the hand joints.
language: eng
source:
identifier: ISSN: 0172-8172 ; E-ISSN: 1437-160X ; DOI: 10.1007/s00296-012-2638-3
fulltext: fulltext
issn:
  • 1437-160X
  • 1437160X
  • 0172-8172
  • 01728172
url: Link


@attributes
ID816099521
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s00296-012-2638-3
sourceidspringer_jour
recordidTN_springer_jour10.1007/s00296-012-2638-3
sourcesystemPC
pqid1518599934
galeid365850166
display
typearticle
titleClinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series
creatorEpis, Oscar ; Filippucci, Emilio ; Delle Sedie, Andrea ; De Matthaeis, Anna ; Bruschi, Eleonora
ispartofRheumatology International, 2014, Vol.34(5), pp.737-742
identifier
subjectRheumatoid arthritis ; Tocilizumab ; Therapy monitoring ; Ultrasonography ; Power Doppler
descriptionThis case series evaluates the clinical and ultrasound response to tocilizumab treatment in patients with rheumatoid arthritis (RA). Six patients with active RA (DAS28 ≥ 3.2) for ≥6 months, refractory to conventional DMARDs or anti-TNF agents, received tocilizumab 8 mg/kg every 4 weeks, as monotherapy or in combination with DMARDs, for 6 months. The following clinical parameters were assessed monthly: number of tender joints (28 and 44 joints), number of swollen joints (28 and 44 joints), DAS28-ESR, DAS28-CRP, VAS score, global health status, health assessment questionnaire, patient global assessment of disease activity, physician global assessment of disease activity, functional assessment of chronic illness therapy (FACIT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). All patients also underwent a gray-scale ultrasonography (US) assessment with power Doppler evaluation at each visit. All clinical parameters improved during the study, versus baseline. This improvement was statistically significant for most parameters 2 months following tocilizumab initiation and was sustained to the end of the observation period. The number of tender joints (44-joint evaluation), the FACIT score, and ESR and CRP concentrations were significantly improved versus baseline values after the first month of tocilizumab treatment. The course of US evaluations mirrored that of clinical parameters; a faster and more evident response was observed for foot joints, with respect to hand joints. This case series suggested the rapid clinical benefit of tocilizumab. Ultrasound assessment showed that the onset of this effect was faster in the foot joints than in the hand joints.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1007/s00296-012-2638-3$$EView_full_text_in_Springer_(Subscribers_only)
search
creatorcontrib
0Epis, Oscar
1Filippucci, Emilio
2Delle Sedie, Andrea
3De Matthaeis, Anna
4Bruschi, Eleonora
titleClinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series
descriptionThis case series evaluates the clinical and ultrasound response to tocilizumab treatment in patients with rheumatoid arthritis (RA). Six patients with active RA (DAS28 ≥ 3.2) for ≥6 months, refractory to conventional DMARDs or anti-TNF agents, received tocilizumab 8 mg/kg every 4 weeks, as monotherapy or in combination with DMARDs, for 6 months. The following clinical parameters were assessed monthly: number of tender joints (28 and 44 joints), number of swollen joints (28 and 44 joints), DAS28-ESR, DAS28-CRP, VAS score, global health status, health assessment questionnaire, patient global assessment of disease activity, physician global assessment of disease activity, functional assessment of chronic illness therapy (FACIT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). All patients also underwent a gray-scale ultrasonography (US) assessment with power Doppler evaluation at each visit. All clinical parameters improved during the study, versus baseline. This improvement was statistically significant for most parameters 2 months following tocilizumab initiation and was sustained to the end of the observation period. The number of tender joints (44-joint evaluation), the FACIT score, and ESR and CRP concentrations were significantly improved versus baseline values after the first month of tocilizumab treatment. The course of US evaluations mirrored that of clinical parameters; a faster and more evident response was observed for foot joints, with respect to hand joints. This case series suggested the rapid clinical benefit of tocilizumab. Ultrasound assessment showed that the onset of this effect was faster in the foot joints than in the hand joints.
subject
0Rheumatoid arthritis
1Tocilizumab
2Therapy monitoring
3Ultrasonography
4Power Doppler
general
010.1007/s00296-012-2638-3
1English
2Springer Science & Business Media B.V.
3SpringerLink
sourceidspringer_jour
recordidspringer_jour10.1007/s00296-012-2638-3
issn
01437-160X
11437160X
20172-8172
301728172
rsrctypearticle
creationdate2014
addtitle
0Rheumatology International
1Clinical and Experimental Investigations
2Rheumatol Int
searchscopespringer_journals_complete
scopespringer_journals_complete
lsr30VSR-Enriched:[pages, galeid, pqid]
sort
titleClinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series
authorEpis, Oscar ; Filippucci, Emilio ; Delle Sedie, Andrea ; De Matthaeis, Anna ; Bruschi, Eleonora
creationdate20140500
facets
frbrgroupid8890234745535340784
frbrtype5
languageeng
creationdate2014
topic
0Rheumatoid Arthritis
1Tocilizumab
2Therapy Monitoring
3Ultrasonography
4Power Doppler
collectionSpringerLink
prefilterarticles
rsrctypearticles
creatorcontrib
0Epis, Oscar
1Filippucci, Emilio
2Delle Sedie, Andrea
3De Matthaeis, Anna
4Bruschi, Eleonora
jtitleRheumatology International
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Epis
1Filippucci
2Delle Sedie
3De Matthaeis
4Bruschi
aufirst
0Oscar
1Emilio
2Andrea
3Anna
4Eleonora
au
0Epis, Oscar
1Filippucci, Emilio
2Delle Sedie, Andrea
3De Matthaeis, Anna
4Bruschi, Eleonora
atitleClinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series
jtitleRheumatology International
stitleRheumatol Int
addtitleClinical and Experimental Investigations
risdate201405
volume34
issue5
spage737
epage742
issn0172-8172
eissn1437-160X
genrearticle
ristypeJOUR
abstractThis case series evaluates the clinical and ultrasound response to tocilizumab treatment in patients with rheumatoid arthritis (RA). Six patients with active RA (DAS28 ≥ 3.2) for ≥6 months, refractory to conventional DMARDs or anti-TNF agents, received tocilizumab 8 mg/kg every 4 weeks, as monotherapy or in combination with DMARDs, for 6 months. The following clinical parameters were assessed monthly: number of tender joints (28 and 44 joints), number of swollen joints (28 and 44 joints), DAS28-ESR, DAS28-CRP, VAS score, global health status, health assessment questionnaire, patient global assessment of disease activity, physician global assessment of disease activity, functional assessment of chronic illness therapy (FACIT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). All patients also underwent a gray-scale ultrasonography (US) assessment with power Doppler evaluation at each visit. All clinical parameters improved during the study, versus baseline. This improvement was statistically significant for most parameters 2 months following tocilizumab initiation and was sustained to the end of the observation period. The number of tender joints (44-joint evaluation), the FACIT score, and ESR and CRP concentrations were significantly improved versus baseline values after the first month of tocilizumab treatment. The course of US evaluations mirrored that of clinical parameters; a faster and more evident response was observed for foot joints, with respect to hand joints. This case series suggested the rapid clinical benefit of tocilizumab. Ultrasound assessment showed that the onset of this effect was faster in the foot joints than in the hand joints.
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
doi10.1007/s00296-012-2638-3
pages737-742
date2014-05